Antibiotic treatment outcomes in community-acquired pneumonia

Simple item page
dc.contributor.authorÇilli A.
dc.contributor.authorSayiner A.
dc.contributor.authorÇelenk B.
dc.contributor.authorŞakar Coşkun A.
dc.contributor.authorKilinç O.
dc.contributor.authorHazar A.
dc.contributor.authorAktaş Samur A.
dc.contributor.authorTaşbakan S.
dc.contributor.authorWaterer G.W.
dc.contributor.authorHavlucu Y.
dc.contributor.authorKiliç Ö.
dc.contributor.authorTokgöz F.
dc.contributor.authorBilge U.
dc.date.accessioned2024-07-22T08:10:07Z
dc.date.available2024-07-22T08:10:07Z
dc.date.issued2018
dc.description.abstractBackground/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a β-lactam, β-lactam and macrolide combination, or a fluoroquinolone. Materials and methods: This prospective cohort study was performed using standardized web-based database sheets from January 2009 to September 2013 in nine tertiary care hospitals in Turkey. Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The most frequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were not different among patients treated with β-lactam, β-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%) died during the hospitalization period. There was no difference in survival among the three treatment groups. Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam, β-lactam and macrolide combination, and fluoroquinolone regimens. © TÜBİTAK.
dc.identifier.DOI-ID10.3906/sag-1709-144
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15072
dc.language.isoEnglish
dc.publisherTurkiye Klinikleri Journal of Medical Sciences
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnti-Bacterial Agents
dc.subjectbeta-Lactams
dc.subjectCommunity-Acquired Infections
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectFluoroquinolones
dc.subjectHospital Departments
dc.subjectHospital Mortality
dc.subjectHospitals
dc.subjectHumans
dc.subjectLength of Stay
dc.subjectMacrolides
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPneumonia
dc.subjectProspective Studies
dc.subjectPseudomonas aeruginosa
dc.subjectStreptococcus pneumoniae
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectalbumin
dc.subjectbeta lactam antibiotic
dc.subjectbeta lactamase inhibitor
dc.subjectceftriaxone
dc.subjectclarithromycin
dc.subjectlevofloxacin
dc.subjectmacrolide
dc.subjectmoxifloxacin
dc.subjectquinoline derived antiinfective agent
dc.subjectantiinfective agent
dc.subjectbeta lactam
dc.subjectmacrolide
dc.subjectquinolone derivative
dc.subjectadult
dc.subjectage
dc.subjectaged
dc.subjectantibiotic resistance
dc.subjectantibiotic therapy
dc.subjectArticle
dc.subjectcerebrovascular accident
dc.subjectchronic kidney failure
dc.subjectchronic obstructive lung disease
dc.subjectclinical trial
dc.subjectcohort analysis
dc.subjectcommunity acquired pneumonia
dc.subjectCURB-65 score
dc.subjectdiabetes mellitus
dc.subjectdrug treatment failure
dc.subjecteosinophil count
dc.subjectEscherichia coli
dc.subjectfollow up
dc.subjectHaemophilus influenzae
dc.subjecthospital mortality
dc.subjecthuman
dc.subjectlength of stay
dc.subjectlung cancer
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectobservational study
dc.subjectoxygen tension
dc.subjectPneumonia Severity Index
dc.subjectprospective study
dc.subjectStaphylococcus aureus
dc.subjectthorax radiography
dc.subjecttreatment outcome
dc.subjectcombination drug therapy
dc.subjectcommunity acquired infection
dc.subjectepidemiology
dc.subjectfemale
dc.subjectgrowth, development and aging
dc.subjecthospital
dc.subjecthospital department
dc.subjectlength of stay
dc.subjectmicrobiology
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectpneumonia
dc.subjectPseudomonas aeruginosa
dc.subjectStreptococcus pneumoniae
dc.subjectturkey (bird)
dc.subjectvery elderly
dc.titleAntibiotic treatment outcomes in community-acquired pneumonia
dc.typeArticle

Files

Collections

Scopus Koleksiyonu